A Leukemic Target with a Thousand Faces: The Mitochondria.
Ontology highlight
ABSTRACT: In the era of personalized medicine greatly improved by molecular diagnosis and tailor-made therapies, the survival rate of acute myeloid leukemia (AML) at 5 years remains unfortunately low. Indeed, the high heterogeneity of AML clones with distinct metabolic and molecular profiles allows them to survive the chemotherapy-induced changes, thus leading to resistance, clonal evolution, and relapse. Moreover, leukemic stem cells (LSCs), the quiescent reservoir of residual disease, can persist for a long time and activate the recurrence of disease, supported by significant metabolic differences compared to AML blasts. All these points highlight the relevance to develop combination therapies, including metabolism inhibitors to improve treatment efficacy. In this review, we summarized the metabol
SUBMITTER: Maffeo B
PROVIDER: S-EPMC10487524 | biostudies-literature | 2023 Aug
REPOSITORIES: biostudies-literature
ACCESS DATA